BioSpace News Archive

Lucira Health, Inc., a medical technology company, announced that it submitted an Emergency Use Authorization application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test.

Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia.

Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people with presbyopia, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%).

Evaxion Biotech A/S today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01.

Relay Therapeutics, Inc. is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 2:15 p.m. PT.

LEXEO Therapeutics, Inc. today announced that R. Nolan Townsend, Chief Executive Officer of LEXEO Therapeutics, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 10:30 AM PT.

Dante Genomics , a global leader in genomics and precision medicine, is pleased to announce that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco next week.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference.

Photocure ASA, The Bladder Cancer Company, announces the publication of the study ‘Clinical and Economic Impact of Blue Light Cystoscopy in the Management of NMIBC* at U.S. Ambulatory Surgical Centers: What is the Site-of-Service Disparity?’ in Urologic Oncology this week.

Tessa Therapeutics Ltd. announced that the company will prioritize development of its allogeneic “off-the-shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy platform, while seeking strategic options for the development of its TT11 autologous CAR-T platform with other companies.